» Articles » PMID: 36001113

TGF-β1/Smad3 Upregulates UCA1 to Promote Liver Fibrosis Through DKK1 and MiR18a

Overview
Specialty General Medicine
Date 2022 Aug 24
PMID 36001113
Authors
Affiliations
Soon will be listed here.
Abstract

TGF-β1 is the strongest cytokine known to promote liver fibrosis. It has been previously demonstrated that the activation of TGF-β1 initiates a temporary collagen accumulation program, which is important for wound repair in several organs. Furthermore, temporary extracellular matrix enhancement often leads to progressive fibrosis, which is accountable for cases of severe morbidity and mortality worldwide. However, its action mechanism has not been fully explored. It was previously reported that UCA1 could promote its occurrence and development in various tumors. Importantly, it was reported that TGF-β1 could activate the expression of UCA1 in liver cancer, gastric cancer, and breast cancer. However, the role of UCA1 in organ fibrosis, including liver fibrosis, remains unreported. The present study reported for the first time that TGF-β1/Smad3 could promote liver fibrosis by upregulating UCA1, which further affected DKK1 and collagen, such as COL1A1, COL1A2, and COL3A1. Meanwhile, UCA1 could competitively bind with miR18a to stabilize Smad3 to constitute a positive feedback pathway, which played a significant role in the promotion of liver fibrosis. Altogether, the present study provides a theoretical basis for devising promising treatment strategies for liver fibrosis. KEY MESSAGES : UCA1 was found to promote the progression of liver fibrosis in vitro. UCA1 is regulated by TGF-β1 and promotes liver fibrosis through the canonical Smad pathway. UCA1 can competitively bind with miR18a, promote liver fibrosis by stabilizing Smad3, and form a UCA1-miR18a/Smad3 positive feedback. UCA1 binds EZH2 to inhibit the DKK1 expression and promote liver fibrosis.

Citing Articles

The interactive role of microRNA and other non-coding RNA in hepatitis B (HBV) associated fibrogenesis.

Sartorius K, Wang Y, Sartorius B, Antwi S, Li X, Chuturgoon A Funct Integr Genomics. 2025; 25(1):24.

PMID: 39847120 DOI: 10.1007/s10142-024-01519-4.


Retinoid X receptor heterodimers in hepatic function: structural insights and therapeutic potential.

Xu R, Zhang L, Pan H, Zhang Y Front Pharmacol. 2024; 15:1464655.

PMID: 39478961 PMC: 11521896. DOI: 10.3389/fphar.2024.1464655.


Implications in Cancer of Nuclear Micro RNAs, Long Non-Coding RNAs, and Circular RNAs Bound by PRC2 and FUS.

Swaminathan G, Rogel-Ayala D, Armich A, Barreto G Cancers (Basel). 2024; 16(5).

PMID: 38473229 PMC: 10930775. DOI: 10.3390/cancers16050868.


KIF18A inactivates hepatic stellate cells and alleviates liver fibrosis through the TTC3/Akt/mTOR pathway.

Zhang H, Xia T, Xia Z, Zhou H, Li Z, Wang W Cell Mol Life Sci. 2024; 81(1):96.

PMID: 38372748 PMC: 10876760. DOI: 10.1007/s00018-024-05114-5.


Fibrosis-the tale of H3K27 histone methyltransferases and demethylases.

Basta M, Petruk S, Mazo A, Walker J Front Cell Dev Biol. 2023; 11:1193344.

PMID: 37476157 PMC: 10354294. DOI: 10.3389/fcell.2023.1193344.


References
1.
Song L, Chen T, Zhao X, Xu Q, Jiao R, Li J . Pterostilbene prevents hepatocyte epithelial-mesenchymal transition in fructose-induced liver fibrosis through suppressing miR-34a/Sirt1/p53 and TGF-β1/Smads signalling. Br J Pharmacol. 2019; 176(11):1619-1634. PMC: 6514378. DOI: 10.1111/bph.14573. View

2.
Loboda A, Sobczak M, Jozkowicz A, Dulak J . TGF-β1/Smads and miR-21 in Renal Fibrosis and Inflammation. Mediators Inflamm. 2016; 2016:8319283. PMC: 5005604. DOI: 10.1155/2016/8319283. View

3.
Henderson N, Rieder F, Wynn T . Fibrosis: from mechanisms to medicines. Nature. 2020; 587(7835):555-566. PMC: 8034822. DOI: 10.1038/s41586-020-2938-9. View

4.
Wrana J, Attisano L, Wieser R, Ventura F, Massague J . Mechanism of activation of the TGF-beta receptor. Nature. 1994; 370(6488):341-7. DOI: 10.1038/370341a0. View

5.
Kim K, Sheppard D, Chapman H . TGF-β1 Signaling and Tissue Fibrosis. Cold Spring Harb Perspect Biol. 2017; 10(4). PMC: 5880172. DOI: 10.1101/cshperspect.a022293. View